Reference5 articles.
1. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer;Yang;N Engl J Med,2003
2. Cancer and Leukemia Group B 90206;Rini;Clin Cancer Res,2004
3. SU011248, a novel tyrosine kinase inhibitor, shows anti-tumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase II trial. ASCO Proceedings, :[abstract];Motzer;J Clin Oncol,2004
4. Preliminary antitumor activity of BAY 43 43–9006 in metastatic renal cell carcinomaand other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). ASCO Proceedings [abstract];Ratain;J Clin Oncol,2004
5. Phase I study of PTK787/ZK222584 (PTK/ZK) in metastaic renal cell carcinoma. ASCO Proceedings [abstract];George;J Clin Oncol,2003
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献